EGFR and non-small cell lung carcinoma: For example, the SCLC component typically harbors bi-allelic inactivation of RB1/TP53 and demonstrates sensitivity to platinum-based chemotherapy (10, 30); the NSCLC components may retain oncogenic drivers such as EGFR mutations or ALK rearrangements (31, 32).